EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer

Nikolaos Soupos, Konstantinos Laschos, Evangelos Bournakis, Euthymios Kostouros, Gerasimos Aravantinos

Forum of Clinical Oncology · 2015

DOI: 10.1515/fco-2015-0014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Forum of Clinical Oncology, 2015. Verfasst von Nikolaos Soupos und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Olaparib is a potent oral inhibitor of PARP 1 & 2 with biological activity in various solid tumours for patients with germline and/or sporadic BRCA mutations. The aim of this review is to present the results of the various studies which show Olaparib’s efficacy in ovarian cancer

Zitieren

APA

Soupos, N., Laschos, K., Bournakis, E., Kostouros, E., & Aravantinos, G. (2015). OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer. Forum of Clinical Oncology. https://doi.org/10.1515/fco-2015-0014

Vancouver

Soupos N, Laschos K, Bournakis E, Kostouros E, Aravantinos G. OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer. Forum of Clinical Oncology. 2015. doi:10.1515/fco-2015-0014

BibTeX
@article{Soupos2015,
  author = {Soupos, Nikolaos and Laschos, Konstantinos and Bournakis, Evangelos and Kostouros, Euthymios and Aravantinos, Gerasimos},
  title = {OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer},
  journal = {Forum of Clinical Oncology},
  year = {2015},
  doi = {10.1515/fco-2015-0014}
}
Kostenlos starten →